Revisão | Características clínicas e tratamento farmacológico da trombocitopenia trombótica com trombose de seio venoso cerebral desencadeada por vacina contra COVID-19.

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review – JAMA Cardiology

Conteúdos relacionados:

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

Comentário no Twitter

Big day! Our paper is now published in JAMA Cardiology! @JAMA_current @JAMACardio @JAMANetwork

COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia with Cerebral Venous Sinus Thrombosis

Full-text: https://t.co/XoY0xoztXT pic.twitter.com/IfAmsxomPy

— John G. Rizk (@JohnGRizk) August 10, 2021